Drug Repurposing Tuberculosis
Drug Repurposing Tuberculosis - Related Videos
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
0 Views •
Cited by 4 •
2016
Here we describe a protocol using the web-based drug repurposing hypothesis generation tool: "RE:fine Drugs." This protocol can be modified to a user's preferences at the level of the query type (gene, drug or disease) and/or the range of available advanced options.
12:17
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
0 Views •
Cited by 24 •
2017
Here we describe a rapid equilibrium dialysis (RED) method to measure drug binding to caseum from pulmonary tuberculosis lesions and cavities. The protocol is also used with a foamy macrophage-derived matrix that is an effective surrogate to caseum.
10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
0 Views •
Cited by 1 •
2017
New models and assays that would improve the early drug development process for next-generation anti-tuberculosis drugs are highly desirable. Here, we describe a quick, inexpensive, and BSL-2 compatible assay to evaluate drug efficacy against Mycobacterium tuberculosis that can be easily adapted for high-throughput screening.
05:14
An Assay to Evaluate Drug Efficacy against a Mycobacterium tuberculosis Infection Model
0 Views •
2025
This video demonstrates an assay to evaluate the efficacy of drugs against Mycobacterium tuberculosis (Mtb) infection. An in vitro infection model containing Mtb/macrophage aggregates is generated that mimics in vivo infection. Upon introducing suitable antibiotics, their efficacy is tested via resuzarin assay to monitor the survival of bacteria with increasing drug concentrations.
03:00
Measuring Drug Binding to Caseum from Tuberculosis Lesions via the Rapid Equilibrium Dialysis Method
0 Views •
2025
Source: Sarathy, J. P. et al. An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions. J. Vis. Exp. (2017)This video demonstrates an in vitro assay for measuring drug binding to caseum from tuberculosis lesions using rapid equilibrium dialysis. It outlines the steps for preparing caseum suspensions, performing dialysis, and calculating the unbound drug fraction to predict drug penetration into caseum.
FAQs
Repurposed candidates can act directly on Mycobacterium tuberculosis or influence host pathways that improve immune control of infection. These routes address different biological problems: antibacterial activity may reduce bacterial growth, whereas host-directed effects may strengthen the response against bacteria. Distinguishing the two mechanisms helps investigators interpret screening results and identify complementary treatment strategies.
Some repurposed drugs may act against persistent bacterial populations, which are relevant to difficult-to-treat tuberculosis. Their activity could broaden the effects of treatment beyond actively growing bacteria and support more effective regimens. Screening for this property is therefore distinct from simply measuring general susceptibility and may reveal candidates with value in challenging infection contexts.
Repurposed drugs may strengthen existing combination regimens by adding antibacterial activity or host-directed effects. They may also provide options for addressing antimicrobial resistance, particularly when standard treatments become less effective. The key value lies in evaluating how a candidate complements other medicines, rather than judging its usefulness only as an isolated compound.
Investigators can combine susceptibility assays, phenotypic screening, and target or pathway analysis. Susceptibility assays examine activity against Mycobacterium tuberculosis, while phenotypic screening identifies useful effects without requiring an initially defined target. Target or pathway analysis then helps clarify how a promising compound may act and whether its effect is antibacterial or host-directed.
Researchers should consider the candidate's observed activity, its possible mechanism, and whether it offers value against persistent bacteria, drug resistance, or difficult-to-treat disease. Existing pharmacology and safety data can support translational assessment, but screening results still need interpretation within combination and host-response contexts. This evaluation helps prioritize compounds for further development.
The approach connects microbial susceptibility with the biology of host control. A candidate may be valuable because it acts against Mycobacterium tuberculosis, modifies a host pathway, or contributes both effects within a treatment strategy. This intersection allows immunology and infection researchers to investigate therapies that address bacterial survival, immune control, and treatment difficulty together.